克隆性造血与房颤患者沉默性脑病变及认知下降的关联
这项前瞻性多中心队列研究纳入1572例房颤患者,通过深度靶向测序检测CHIP相关变异,并在基线和2年时进行脑MRI及7年认知评估。结果显示CHIP携带者基线脑微出血和脑白质病变的比值显著升高,2年随访新发微出血计数和脑白质病变体积增加,7年蒙特利尔认知评估评分下降更明显。
要点
- 房颤患者中CHIP携带率为22%,以DNMT3A和TET2变异最常见。
- CHIP携带者基线脑微出血(OR 1.45)和脑白质病变(OR 1.56)风险显著增加。
- CHIP携带者7年认知下降更明显(β -0.53),尤其DNMT3A和ASXL1变异携带者。
核心结论
- 在房颤患者中,CHIP独立关联于沉默性脑病变负担及进展增加和认知下降加速。
研究设计与样本
- 前瞻性多中心队列研究,纳入2014至2017年入组的1572例房颤患者。
- 所有参与者接受CHIP相关序列变异的深度靶向测序、脑磁共振成像和标准化认知评估。
- 横断面分析在199例韩国房颤患者队列中进行外部验证。
主要发现
- 1572例房颤患者(平均年龄72.5±8.3岁,女性26%)中342例(22%)携带CHIP序列变异,最常见为DNMT3A(49.4%)和TET2(28.3%)。
- CHIP携带者基线脑微出血的OR为1.45(95%CI 1.09-1.93),脑白质病变的OR为1.56(95%CI 1.20-2.04)。
- 非DNMT3A序列变异携带者脑微出血OR为1.79(95%CI 1.25-2.55),脑白质病变OR为1.80(95%CI 1.25-2.62)。
- 多个CHIP序列变异进一步增加脑微出血(OR 1.36,95%CI 1.10-1.69)和脑白质病变(OR 1.41,95%CI 1.15-1.75)的比值。
- 大CHIP克隆(变异等位基因频率>10%)与更高的脑白质病变体积相关;7年随访CHIP携带者蒙特利尔认知评估评分较非携带者更低(β -0.53,95%CI -1.02至-0.03)。
临床怎么用
- 对房颤患者可考虑CHIP检测以识别沉默性脑病变和认知下降高风险人群。
- CHIP携带者(尤其非DNMT3A变异或大克隆)可能需要更密切的脑影像和认知监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP) has been associated with cardiovascular disease, but its relationship with silent brain lesions and cognitive decline in patients with atrial fibrillation (AF) is unclear. METHODS: In this prospective, multicenter cohort study, we included 1572 patients with AF enrolled between 2014 and 2017. All participants underwent deep-targeted sequencing for CHIP-associated sequence variations, brain magnetic resonance imaging, and standardized cognitive assessments. CHIP carrier status (overall, DNMT3A carrier, and non-DNMT3A carrier) was evaluated in relation to prevalent and incident silent brain lesions. Silent brain lesions were defined as large noncortical or cortical infarcts, small noncortical infarcts, microbleeds, and white matter lesions (WMLs), and were assessed at baseline and after 2 years with magnetic resonance imaging. Cross-sectional analyses were externally validated in a cohort of 199 patients with AF. Cognitive function was evaluated through 7 years using the Montreal Cognitive Assessment. Associations were analyzed using multivariable-adjusted logistic and linear regression models. RESULTS: Among 1572 patients with AF (mean±SD age, 72.5±8.3 years; 26% women), 342 (22%) carried CHIP sequence variations, most commonly in DNMT3A (49.4%) and TET2 (28.3%). CHIP carriers had significantly higher odds of cerebral microbleeds (odds ratio [OR], 1.45 [95% CI, 1.09 to 1.93]) and WMLs (OR, 1.56 [95% CI, 1.20 to 2.04]) at baseline, particularly with non-DNMT3A sequence variations (microbleeds: OR, 1.79 [95% CI, 1.25 to 2.55]; WMLs: OR, 1.80 [95% CI, 1.25 to 2.62]). A similar trend was observed in an independent AF patient cohort from Korea limited to TET2 sequence variations. Presence of multiple CHIP sequence variations further increased the odds of microbleeds (OR, 1.36 [95% CI, 1.10 to 1.69]) and WMLs (OR, 1.41 [95% CI, 1.15 to 1.75]), and large CHIP clones (variant allele frequency >10%) were associated with higher WML volumes. At 2-year follow-up, CHIP was associated with new cerebral microbleed counts and greater WML volume. Over 7 years, CHIP carriers exhibited greater cognitive decline, with a lower Montreal Cognitive Assessment score compared with noncarriers (β -0.53 [95% CI, -1.02 to -0.03]). The decline was more pronounced in DNMT3A and ASXL1 sequence variation carriers. CONCLUSIONS: In patients with AF, CHIP was independently associated with a greater burden and progression of silent brain lesions and with accelerated cognitive decline. GRAPHIC ABSTRACT: A graphic abstract is available for this article.
引用
- Meyre PB, Ahn HJ, Ehlert CA, et al. Association of Clonal Hematopoiesis With Silent Brain Lesions and Cognitive Decline in Patients With Atrial Fibrillation. Circulation. 2026. PMID: 42610248. doi:10.1161/CIRCULATIONAHA.126.079459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。